BICX BioCorrx Inc

BioCorRx Offers Free Access to the UnCraveRxâ„¢ Mobile Platform for Weight Loss Management During COVID-19 Pandemic

BioCorRx Offers Free Access to the UnCraveRx™ Mobile Platform for Weight Loss Management During COVID-19 Pandemic

ANAHEIM, CA, April 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRx™ App for a limited time. Anyone interested can download the UnCraveRx™ App online at or through the Android or iOS app store. The app includes cardio, strength training, endurance fitness classes that cover a range of fitness styles, nutrition advice, and lifestyle support. It also offers tools to track calorie intake and expenditure, overall physical activity, and distance tracking.

Lourdes Felix, CFO, President and Director, stated, “Unfortunately, the COVID-19 pandemic is forcing millions of people around the world to adjust to life indoors. During the quarantine, it is important for people to have access to exercise and nutritional programs in order to boost the immune system and also provide some stress relief. The UnCraveRx™ app features on-demand virtual lifestyle, fitness, nutrition support and lifestyle modification group support. We want the UnCraveRx™ to serve as a platform for people to be able to learn about what it takes to make good choices for their bodies and help people find the advantage they need in order to meet their lifestyle goals during this time and beyond.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit for more information on the BioCorRx Recovery Program. BioCorRx does not diagnose, treat, or sell the program to patients. The UnCraveRx™ Weight Loss Program is also a medication-assisted program; please visit for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit . 

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.



714-462-4880



Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304

EN
10/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE

BioCorRx Reports Business Update for the Second Quarter of 2024

BioCorRx Reports Business Update for the Second Quarter of 2024 ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to...

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurologi...

 PRESS RELEASE

BioCorRx Reports Business Update for 2023

BioCorRx Reports Business Update for 2023 ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid ...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch